Table 1. Socio-demographic and treatment characteristics of women initiating a hormonal therapy, with or without metastases, between 1 January 2006 and 31 December 2007 in EGB database.
| All cohort N=600 | Subcohort of women without metastases N=564 | |
|---|---|---|
|
Age at inclusion – years | ||
| <50 | 121 (20.2) | 112 (19.9) |
| [50–69] | 283 (47.2) | 266 (47.2) |
| ⩾70 | 196 (32.7) | 186 (33.0) |
|
Hormonal therapy delivered during follow-up,
n
(%) | ||
| Tamoxifen only | 107 (17.9) | 104 (18.4) |
| AI only | 358 (59.7) | 330 (58.5) |
| Switch from AI to tamoxifen | 40 (6.7) | 39 (6.9) |
| Switch from tamoxifen to AI | 58 (9.7) | 54 (9.6) |
| Multiple switches | 37 (6.2) | 37 (6.6) |
|
Number of switches during follow-up,
n
(%) | ||
| 0 | 465 (77.5) | 434 (77.0) |
| 1 | 98 (16.3) | 93 (16.5) |
| ⩾2 | 37 (6.2) | 37 (6.6) |
|
Prescriber specialty for the first hormonal therapy prescription,
n
(%) | ||
| Unknown | 8 (1.3) | 7 (1.2) |
| General practitioners | 312 (52.0) | 294 (52.1) |
| Breast cancer specialists | 282 (42.7) | 242 (42.9) |
| Other | 32 (5.3) | 21 (3.7) |
|
Professional activity of prescribers for the first hormonal therapy prescription,
n
(%) | ||
| Unknown | 3 (0.5) | 2 (0.4) |
| Private | 305 (50.8) | 290 (51.4) |
| Salaried | 292 (48.7) | 272 (48.2) |
|
Breast cancer diagnosis at the last hospitalisation before inclusion,
n
(%) | ||
| Non identified | 164 (27.3) | 136 (24.1) |
| Localised breast cancer | 7 (1.2) | 7 (1.3) |
| Invasive breast cancer | 429 (71.5) | 421 (74.6) |
|
In the 12 month-period before inclusion,
n
(%) | ||
| Affiliation to CMU | 18 (3.0) | 17 (3.0) |
| Breast cancer ALD | 517 (86.2) | 500 (88.7) |
| Breast cancer medical management | ||
| Imagery | 69 (11.5) | 62 (11.0) |
| Biopsy | 20 (3.3) | 17 (3.0) |
| Reconstructive surgery | 14 (2.3) | 14 (2.5) |
| Curative surgery only | 208 (34.7) | 206 (36.5) |
| Chemotherapy only | 28 (4.7) | 12 (2.1) |
| Radiotherapy only | 5 (0.8) | 5 (0.9) |
| Curative surgery and radiotherapy | 52 (8.7) | 51 (9.0) |
| Curative surgery and chemotherapy | 113 (18.8) | 111 (19.7) |
| Chemotherapy and radiotherapy | 4 (0.7) | 4 (0.7) |
| Curative surgery, radiotherapy and chemotherapy | 58 (9.7) | 57 (10.1) |
| Breast cancer metastases, n (%) | ||
| 0 | 564 (94.0) | 564 (100.0) |
| 1 | 23 (3.8) | — |
| ⩾2 | 13 (2.2) | — |
Abbreviations: AI=aromatase inhibitors; ALD=registration with one of the 30 major long-standing diseases (Affection Longue Durée); CMU-c=full healthcare coverage for patients with low income (Couverture Médicale Universelle); EGB=Echantillon Généraliste de Bénéficiaires.